Moderna Surges as Barron's Declares It 'Too Cheap'
Moderna stock skyrockets in the S&P 500 after Barron's highlights it as 'too cheap' and a top 10 pick for 2025. Discover why investors are watching closely.
Moderna was the best-performing stock in the S&P 500 as Barron's called it 'too cheap' and named it a top 10 pick for 2025.